News Search Results
Apr 07, 2025, 10:30 ET US Single-Cell Analysis Market worth US$2,695.3 million by 2029 with 14.3% CAGR | MarketsandMarkets™
(US), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Standard BioTools (US), Corning Incorporated (US), Cytek Biosciences (US), Revvity (US), Bio-Techne (US), PacBio (US), Bruker (US), Promega Corporation (US), Fluent BioSciences (US), RareCyte, Inc. (US), Cell Microsystems (US), and NanoCellect Biomedical
More news about: MarketsandMarkets
Apr 07, 2025, 08:30 ET ALZpath Named 2025 BRONZE Edison Award Winner for its Proprietary pTau217 Antibody, a Key Biomarker Driving Blood-Based Alzheimer's Disease Diagnostics
licensing agreements with leading global diagnostic and research organizations. These include Roche, Beckman Coulter, Bio-Techne, Alamar Biosciences, and Quanterix. Additionally, ALZpath partners with world-class laboratories, such as Neurocode, to further expand its reach and
More news about: ALZpath, Inc.
Apr 02, 2025, 07:00 ET Leica Biosystems and Bio-Techne Expand Partnership to Enable Protease-Free Workflows for Automated Spatial Multiomics on the BOND RX Research Staining Instrument
In Diagnostic Procedures. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into
More news about: Bio-Techne Corporation
Apr 01, 2025, 07:00 ET Data Showcasing ALZpath's Proprietary pTau217 Antibody at AD/PD™ 2025 Demonstrates High Rate of Reliability and Scalability for Alzheimer's Disease Research and Diagnosis
Related Neurological Disorders (AD/PD™). The data is based on recent studies conducted by industry leaders, including Beckman Coulter Diagnostics, Bio-Techne, and Neurocode, and will be presented in seven symposia, seven oral presentations, and two poster presentations. Alzheimer's disease and related
More news about: ALZpath, Inc.
Mar 26, 2025, 07:00 ET Bio-Techne Announces New Customer Experience Centre in Düsseldorf, Germany
from multiple European markets. About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into
More news about: Bio-Techne Corporation
Mar 25, 2025, 09:00 ET ALZpath Adds Biotech Veteran to Board of Directors and Names Prominent Global Researcher as Distinguished Scientific Advisor
licensing agreements with leading global diagnostic and research organizations. These include Roche, Beckman Coulter, Bio-Techne, Alamar Biosciences, and Quanterix. Additionally, ALZpath partners with world-class laboratories, such as Neurocode, to further expand its reach and
More news about: ALZpath, Inc.
Mar 24, 2025, 07:00 ET Bio-Techne to Highlight Advances in the Detection of Clinically Relevant Biomarkers using RNAscope Technologies at the 2025 USCAP Annual Meeting
in diagnostic procedures. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into
More news about: Bio-Techne Corporation
Mar 18, 2025, 07:00 ET ALZpath Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
being developed for clinical use by Roche, Beckman Coulter, as well as other leading tests used in research from Bio-Techne, Alamar Biosciences, and Quanterix. Notably, Roche and Beckman Coulter's pTau217 assays have received breakthrough
More news about: ALZpath, Inc.
Mar 12, 2025, 14:15 ET Global Markets for 3D Cultures and Organoids: Trends Analysis with Forecast
2029, at a CAGR of 12.7% during the forecast period. Market leaders include: • 3D Biotek LLC • Bio-Techne • Cellink • Charles River Laboratories • Cherry Biotech • Corning Inc. •
More news about: BCC Research LLC
Mar 10, 2025, 07:00 ET Bio-Techne Begins Shipping Leo - A Next Generation High-Throughput Simple Western System
MINNEAPOLIS, March 10, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it has begun shipping the Leo™ System, powered by Simple Western™ Technology. Leo expands upon existing
More news about: Bio-Techne Corporation
Mar 03, 2025, 17:31 ET Global In Situ Hybridization Market to Grow at a CAGR of ~7% by 2032 | DelveInsight
Biocare Medical, LLC, Genemed Biotechnologies, Inc., NeoGenomics Laboratories, Advanced Cell Diagnostics, Inc., BioView, Bio-Rad Laboratories, Inc., Bio-Techne, QIAGEN, BioGenex, ZYTOVISION GmbH, Promega Corporation, Illumina, Inc., Danaher Corporation, and several others, are currently operating in the
More news about: DelveInsight Business Research, LLP
Mar 03, 2025, 07:00 ET Bio-Techne Launches New Panel Resolving Hard-to-Decipher Carrier Screening Genes
[email protected] About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into
More news about: Bio-Techne Corporation
Feb 27, 2025, 07:00 ET Bio-Techne to Present at Investor Conferences
https://investors.bio-techne.com/ir-calendar. About Bio-TechneBio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities. Bio-Techne products assist scientific investigations into
More news about: Bio-Techne Corporation